According to degree size, the order of the core genes was epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) A, AKT1, STAT3, TP53, ERBB2, PIK3CA, HSP90AA1, mTOR, SRC, CASP3, matrix metalloproteinase 9 (MMP9), IL2, NRAS, PTPN11, TNF, PTGS2, and FGF2. These findings indicate that these may be core genes targeted by YXTMD in the treatment of CHD with BSS. This evidence concerns the gene TP53 and coronary artery disorder.